Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 2Suspended 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Breast Neoplasms 5NSCLC 3Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma of Lung 2Recurrence 1Lung Neoplasms 1Head and Neck Neoplasms 1HER-2 Positive Advanced Gastric Cancer 1Advanced Solid Tumor 1Advanced Solid Malignancies 1

Interventions

Pemetrexed 14Carboplatin 13osimertinib 11Drug Therapy 9aflutinib 8Gefitinib 8Radiotherapy 6Docetaxel 6Cisplatin 6pembrolizumab 5anlotinib 5Radiosurgery 5Paclitaxel 5icotinib 4Vinorelbine 4Gemcitabine 4Erlotinib Hydrochloride 4tislelizumab 3camrelizumab 3apatinib 3HM781-36B 3toripalimab 2spartalizumab 2rezivertinib 2dacomitinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NSCLC × HM781-36B × Clear all
NCT05378763 2026-05-22

PINNACLE

Spectrum Pharmaceuticals, Inc

Phase 3 Suspended
268 enrolled
Thoracic

NSCLC

NCT03318939 2024-04-03

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Spectrum Pharmaceuticals, Inc

Phase 2 Terminated
648 enrolled
Thoracic

NSCLC

NCT04044170 2020-11-17

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Hanmi Pharmaceutical Company Limited

Phase 2 Terminated
5 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡